Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease

Publication date: Available online 8 June 2018
Source:Medical Hypotheses
Author(s): Muhammed Khairujjaman Mazumder, Rajib Paul, Banashree Chetia Phukan, Ankumoni Dutta, Jayasree Chakrabart, Pallab Bhattacharya, Anupom Borah
Loss of dopamine containing neurons in substantia nigra pars compacta of midbrain and resultant depletion of dopamine in striatum is the cause Parkinson's disease (PD) which is associated with motor abnormalities. Replenishment of dopamine by oral supplementation of its precursor, the levodopa (L-DOPA), remains the primary mode of treatment of PD despite its potential side-effects after prolonged use in patients. To reduce the daily dosing of L-DOPA in patients, inhibitors of dopamine catabolizing enzymes particularly monoamine oxidase-B (MAO-B) are prescribed. The most widely used MAO-B inhibitor to maintain the bioavailability of dopamine in brain of PD patients is L-deprenyl despite of its potential side-effect. The present study identified Garcinol as a potential candidate in the treatment paradigm of PD by virtue of its exorbitant MAO-B inhibitory potentials. The inhibitory potential is comparable to known MAO-B inhibitors, which was evaluated by using molecular docking technique. Owing to its known antioxidant, anti-inflammatory and cathecol-o-methyl transferase inhibitory potential the molecule would also confer neuroprotection as well, and thus, the present study is of immense significance in the treatment paradigm of PD.



https://ift.tt/2HuGo0N